

Boris Bastian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8060483/publications.pdf>

Version: 2024-02-01

201
papers

30,849
citations

6613

79
h-index

4645

170
g-index

225
all docs

225
docs citations

225
times ranked

27710
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes. <i>Genome Medicine</i> , 2022, 14, .	8.2	13
2	Iris and Ciliary Body Melanocytomas Are Defined by Solitary GNAQ Mutation Without Additional Oncogenic Alterations. <i>Ophthalmology</i> , 2022, 129, 1429-1439.	5.2	2
3	Functional characterization of uveal melanoma oncogenes. <i>Oncogene</i> , 2021, 40, 806-820.	5.9	39
4	Fusion partners of NTRK3 affect subcellular localization of the fusion kinase and cytomorphology of melanocytes. <i>Modern Pathology</i> , 2021, 34, 735-747.	5.5	20
5	Multiple desmoplastic Spitz nevi with BRAF fusions in a patient with ring chromosome 7 syndrome. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 987-993.	3.3	9
6	Melanoma pathology: new approaches and classification*. <i>British Journal of Dermatology</i> , 2021, 185, 282-293.	1.5	25
7	Evaluation of Crizotinib Treatment in a Patient With Unresectable <i>GOPC-ROS1</i> Fusion Agminated Spitz Nevi. <i>JAMA Dermatology</i> , 2021, 157, 836-841.	4.1	9
8	MicroRNA Ratios Distinguish Melanomas from Nevi. <i>Journal of Investigative Dermatology</i> , 2020, 140, 164-173.e7.	0.7	32
9	Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 439-449.	7.0	64
10	Melanoma to Vitiligo: The Melanocyte in Biology & Medicine—Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting. <i>Journal of Investigative Dermatology</i> , 2020, 140, 269-274.	0.7	2
11	Melanocytic tumors with MAP3K8 fusions: report of 33 cases with morphological-genetic correlations. <i>Modern Pathology</i> , 2020, 33, 846-857.	5.5	38
12	Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features. <i>Ophthalmology</i> , 2020, 127, 804-813.	5.2	39
13	Spitz melanoma is a distinct subset of spitzoid melanoma. <i>Modern Pathology</i> , 2020, 33, 1122-1134.	5.5	67
14	The genomic landscapes of individual melanocytes from human skin. <i>Nature</i> , 2020, 586, 600-605.	27.8	79
15	Eruptive Spitz nevus, a striking example of benign metastasis. <i>Scientific Reports</i> , 2020, 10, 16216.	3.3	13
16	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020, 587, 126-132.	27.8	221
17	769P APOBEC signatures and high tumour mutational burden as predictors of clinical outcomes and response to therapy in patients with urothelial carcinoma. <i>Annals of Oncology</i> , 2020, 31, S593.	1.2	1
18	The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 500-522.	2.5	239

#	ARTICLE	IF	CITATIONS
19	The Tumor Suppressor BAP1 Regulates the Hippo Pathway in Pancreatic Ductal Adenocarcinoma. <i>Cancer Research</i> , 2020, 80, 1656-1668.	0.9	18
20	The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. <i>Brain Pathology</i> , 2019, 29, 85-96.	4.1	88
21	Ocular Melanoma. , 2019, , 453-468.		0
22	Spitz Tumors. , 2019, , 395-410.		0
23	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. <i>Nature Communications</i> , 2019, 10, 3163.	12.8	205
24	The genetic evolution of metastatic uveal melanoma. <i>Nature Genetics</i> , 2019, 51, 1123-1130.	21.4	148
25	Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. <i>Cell Reports</i> , 2019, 29, 573-588.e7.	6.4	62
26	Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. <i>Nature Communications</i> , 2019, 10, 353.	12.8	99
27	Targeted Genomic Profiling of Acral Melanoma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1068-1077.	6.3	118
28	Next-Generation Sequencing of Uveal Melanoma for Detection of Genetic Alterations Predicting Metastasis. <i>Translational Vision Science and Technology</i> , 2019, 8, 18.	2.2	44
29	Association of Indoor Tanning Exposure With Age at Melanoma Diagnosis and BRAF V600E Mutations. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1228-1231.	6.3	4
30	Ewing sarcoma in a child with neurofibromatosis type 1. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004580.	1.2	0
31	Filigree-like Rete Ridges, Lobulated Nests, Rosette-like Structures, and Exaggerated Maturation Characterize Spitz Tumors With NTRK1 Fusion. <i>American Journal of Surgical Pathology</i> , 2019, 43, 737-746.	3.7	55
32	Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. <i>Modern Pathology</i> , 2019, 32, 88-99.	5.5	76
33	The tumor suppressor <i>BAP1</i> cooperates with <i>BRAFV600E</i> to promote tumor formation in cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 269-279.	3.3	9
34	The genetic landscape of gliomas arising after therapeutic radiation. <i>Acta Neuropathologica</i> , 2019, 137, 139-150.	7.7	57
35	PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 778-783.	4.9	6
36	A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. <i>Nature Communications</i> , 2018, 9, 810.	12.8	56

#	ARTICLE	IF	CITATIONS
37	Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway. <i>Acta Neuropathologica</i> , 2018, 135, 485-488.	7.7	54
38	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. <i>Acta Neuropathologica</i> , 2018, 135, 635-638.	7.7	17
39	Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF- κ B pathway activation. <i>Modern Pathology</i> , 2018, 31, 660-673.	5.5	76
40	Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts. <i>Acta Neuropathologica Communications</i> , 2018, 6, 95.	5.2	13
41	Human tumor genomics and zebrafish modeling identify <i>SPRED1</i> loss as a driver of mucosal melanoma. <i>Science</i> , 2018, 362, 1055-1060.	12.6	123
42	Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. <i>Cancer Cell</i> , 2018, 34, 56-68.e9.	16.8	113
43	Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution. <i>Cancer Cell</i> , 2018, 34, 45-55.e4.	16.8	157
44	Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. <i>Acta Neuropathologica</i> , 2018, 136, 339-343.	7.7	37
45	The genetic landscape of ganglioglioma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 47.	5.2	130
46	Spitz Tumors. , 2018, , 1-16.		0
47	Ocular Melanoma. , 2018, , 1-16.		0
48	Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. <i>Neuro-Oncology</i> , 2017, 19, now254.	1.2	155
49	RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. <i>Cancer Cell</i> , 2017, 31, 685-696.e6.	16.8	113
50	Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. <i>Annals of Oncology</i> , 2017, 28, 1380-1387.	1.2	134
51	Multiple Merkel cell carcinomas: Late metastasis or multiple primary tumors? A molecular study. <i>JAAD Case Reports</i> , 2017, 3, 131-134.	0.8	6
52	Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. <i>Scientific Reports</i> , 2017, 7, 44206.	3.3	28
53	Combined activation of MAP kinase pathway and β -catenin signaling cause deep penetrating nevi. <i>Nature Communications</i> , 2017, 8, 644.	12.8	107
54	Mutations in the promoter of the telomerase gene <i>TERT</i> contribute to tumorigenesis by a two-step mechanism. <i>Science</i> , 2017, 357, 1416-1420.	12.6	224

#	ARTICLE	IF	CITATIONS
55	Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?. <i>Cancer Genetics</i> , 2017, 216-217, 74-78.	0.4	3
56	Filling the gaps in the genomic catalogue of melanoma subtypes. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 508-509.	3.3	1
57	Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. <i>Modern Pathology</i> , 2017, 30, 246-254.	5.5	95
58	CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. <i>PLoS Computational Biology</i> , 2016, 12, e1004873.	3.2	1,260
59	From melanocytes to melanomas. <i>Nature Reviews Cancer</i> , 2016, 16, 345-358.	28.4	596
60	<sc>NTRK3</sc> kinase fusions in Spitz tumours. <i>Journal of Pathology</i> , 2016, 240, 282-290.	4.5	128
61	The state of melanoma: challenges and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 404-416.	3.3	77
62	Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation. <i>Acta Neuropathologica</i> , 2016, 132, 757-760.	7.7	32
63	Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. <i>Modern Pathology</i> , 2016, 29, 1012-1027.	5.5	54
64	Inactivating <i>MUTYH</i> germline mutations in pediatric patients with high-grade midline gliomas. <i>Neuro-Oncology</i> , 2016, 18, 752-753.	1.2	20
65	The Genetic Evolution of Melanoma. <i>New England Journal of Medicine</i> , 2016, 374, 993-996.	27.0	26
66	Congenital uveal melanoma?. <i>Survey of Ophthalmology</i> , 2016, 61, 59-64.	4.0	10
67	Biology of advanced uveal melanoma and next steps for clinical therapeutics. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 135-147.	3.3	81
68	Clinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions. <i>American Journal of Surgical Pathology</i> , 2015, 39, 581-591.	3.7	129
69	Clinical activity of the <sc>MEK</sc> inhibitor trametinib in metastatic melanoma containing <i><sc>BRAF</sc></i> kinase fusion. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 607-610.	3.3	70
70	Metastatic Melanoma in Association With a Giant Congenital Melanocytic Nevus in an Adult. <i>American Journal of Dermatopathology</i> , 2015, 37, 487-494.	0.6	22
71	Activating MET kinase rearrangements in melanoma and Spitz tumours. <i>Nature Communications</i> , 2015, 6, 7174.	12.8	139
72	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. <i>Clinical Cancer Research</i> , 2015, 21, 2289-2296.	7.0	128

#	ARTICLE	IF	CITATIONS
73	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	28.9	2,562
74	The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. <i>British Journal of Cancer</i> , 2015, 112, 1326-1331.	6.4	30
75	A caveolin-dependent and PI3K/AKT-independent role of PTEN in β -catenin transcriptional activity. <i>Nature Communications</i> , 2015, 6, 8093.	12.8	58
76	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. <i>Nature Genetics</i> , 2015, 47, 1194-1199.	21.4	221
77	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10995-11000.	7.1	146
78	The Genetic Evolution of Melanoma from Precursor Lesions. <i>New England Journal of Medicine</i> , 2015, 373, 1926-1936.	27.0	824
79	Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. <i>Nature Communications</i> , 2014, 5, 3116.	12.8	521
80	A Mouse Model Uncovers LKB1 as an UVB-Induced DNA Damage Sensor Mediating CDKN1A (p21WAF1/CIP1) Degradation. <i>PLoS Genetics</i> , 2014, 10, e1004721.	3.5	40
81	Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 37-47.	3.3	112
82	Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. <i>Oncogene</i> , 2014, 33, 4724-4734.	5.9	174
83	Regulatory network decoded from epigenomes of surface ectoderm-derived cell types. <i>Nature Communications</i> , 2014, 5, 5442.	12.8	25
84	Ambiguous Melanocytic Tumors With Loss of 3p21. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1088-1095.	3.7	75
85	Melanoma BRAF Fusions Letter. <i>Clinical Cancer Research</i> , 2014, 20, 6631-6631.	7.0	8
86	Fluorescence In Situ Hybridization as an Ancillary Tool in the Diagnosis of Ambiguous Melanocytic Neoplasms. <i>American Journal of Surgical Pathology</i> , 2014, 38, 824-831.	3.7	70
87	The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2014, 9, 239-271.	22.4	392
88	Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma. <i>International Journal of Cancer</i> , 2014, 134, 244-248.	5.1	14
89	Chromosomal Copy Number Analysis in Melanoma Diagnostics. <i>Methods in Molecular Biology</i> , 2014, 1102, 199-226.	0.9	16
90	In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 671-673.	3.3	28

#	ARTICLE	IF	CITATIONS
91	Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP. <i>Cancer Cell</i> , 2014, 25, 822-830.	16.8	391
92	MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13845-13850.	7.1	29
93	Clonal BRAF Mutations in Melanocytic Nevi and Initiating Role of BRAF in Melanocytic Neoplasia. <i>Journal of the National Cancer Institute</i> , 2013, 105, 917-919.	6.3	92
94	SOX10 Ablation Arrests Cell Cycle, Induces Senescence, and Suppresses Melanomagenesis. <i>Cancer Research</i> , 2013, 73, 5709-5718.	0.9	70
95	Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells. <i>Cancer Cell</i> , 2013, 23, 811-825.	16.8	553
96	Targeting Activated KIT Signaling for Melanoma Therapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 3288-3290.	1.6	16
97	Recurrent <scp>BRAF</scp> kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 845-851.	3.3	114
98	Molecular Pathology of Cutaneous Melanoma and Nonmelanoma Skin Cancer. , 2013, , 269-306.		0
99	A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of BAP1 Expression. <i>American Journal of Surgical Pathology</i> , 2012, 36, 818-830.	3.7	264
100	Raising the bar for melanoma cancer gene discovery. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 708-709.	3.3	3
101	Sunitinib Therapy for Melanoma Patients with <i>KIT</i> Mutations. <i>Clinical Cancer Research</i> , 2012, 18, 1457-1463.	7.0	197
102	Erythropoietin receptor contributes to melanoma cell survival in vivo. <i>Oncogene</i> , 2012, 31, 1649-1660.	5.9	46
103	GNA11 (guanine nucleotide binding protein (G protein), alpha 11 (Gq class)). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2012, , .	0.1	0
104	GNAQ (guanine nucleotide binding protein (G protein), q polypeptide). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2012, , .	0.1	0
105	An unconventional deep penetrating melanocytic nevus with microscopic involvement of regional lymph nodes. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 25-28.	1.3	20
106	GNAQ and GNA11 mutations in melanocytomas of the central nervous system. <i>Acta Neuropathologica</i> , 2012, 123, 457-459.	7.7	60
107	Melanocytic nevi. , 2012, , 1150-1220.		1
108	Germline mutations in BAP1 predispose to melanocytic tumors. <i>Nature Genetics</i> , 2011, 43, 1018-1021.	21.4	662

#	ARTICLE	IF	CITATIONS
109	<i>BRAF</i> mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 345-351.	3.3	180
110	The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 879-897.	3.3	225
111	Metastatic Melanoma With Striking Adenocarcinomatous Differentiation Illustrating Phenotypic Plasticity in Melanoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1413-1418.	3.7	25
112	Assessment of Copy Number Status of Chromosomes 6 and 11 by FISH Provides Independent Prognostic Information in Primary Melanoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1146-1150.	3.7	60
113	Genetic alterations in uveal melanoma. <i>Expert Review of Ophthalmology</i> , 2011, 6, 129-132.	0.6	0
114	Nodular lesions arising in a large congenital melanocytic naevus in a newborn with eruptive disseminated Spitz naevi. <i>British Journal of Dermatology</i> , 2011, 165, 1138-1142.	1.5	26
115	Molecular-Microscopical Correlation in Dermatopathology. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 324-326.	1.3	12
116	An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second "primary" tumor. <i>Journal of Cutaneous Pathology</i> , 2011, 38, no-no.	1.3	15
117	KIT as a Therapeutic Target in Metastatic Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2327.	7.4	755
118	Progress in the delivery of siRNA therapeutics: Potential in uveal melanoma. <i>Drugs of the Future</i> , 2011, 36, 229.	0.1	5
119	Use of Fluorescence In situ Hybridization (FISH) to Distinguish Intranodal Nevus From Metastatic Melanoma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 231-237.	3.7	86
120	Mutation-driven drug development in melanoma. <i>Current Opinion in Oncology</i> , 2010, 22, 178-183.	2.4	94
121	Molecular Analysis of a Case of Nevus of Ota Showing Progressive Evolution to Melanoma With Intermediate Stages Resembling Cellular Blue Nevus. <i>American Journal of Dermatopathology</i> , 2010, 32, 301-305.	0.6	59
122	KIT as a Therapeutic Target in Melanoma. <i>Journal of Investigative Dermatology</i> , 2010, 130, 20-27.	0.7	99
123	Germline Variation Controls the Architecture of Somatic Alterations in Tumors. <i>PLoS Genetics</i> , 2010, 6, e1001136.	3.5	35
124	Beyond BRAF in Melanoma. <i>Current Topics in Microbiology and Immunology</i> , 2010, 355, 99-117.	1.1	14
125	Comment on "Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT": <i>Journal of Investigative Dermatology</i> , 2010, 130, 2330-2331.	0.7	1
126	Loss of the p53/p63 Regulated Desmosomal Protein Perp Promotes Tumorigenesis. <i>PLoS Genetics</i> , 2010, 6, e1001168.	3.5	63

#	ARTICLE	IF	CITATIONS
127	Somatic Mutation of Epidermal Growth Factor Receptor in a Small Subset of Cutaneous Squamous Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2010, 130, 901-903.	0.7	26
128	Mutations in <i>GNA11</i> in Uveal Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 2191-2199.	27.0	1,312
129	Genetic and morphologic features for melanoma classification. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 763-770.	3.3	130
130	Elevated Cutaneous Smad Activation Associates with Enhanced Skin Tumor Susceptibility in Organ Transplant Recipients. <i>Clinical Cancer Research</i> , 2009, 15, 5101-5107.	7.0	12
131	Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma. <i>Molecular Cancer Research</i> , 2009, 7, 41-54.	3.4	112
132	The Presence of Polyomavirus in Non-Melanoma Skin Cancer in Organ Transplant Recipients Is Rare. <i>Journal of Investigative Dermatology</i> , 2009, 129, 250-252.	0.7	54
133	Absence of Somatic Mutations of NEMO in Keratoacanthoma. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2518-2520.	0.7	0
134	Frequent somatic mutations of <i>GNAQ</i> in uveal melanoma and blue naevi. <i>Nature</i> , 2009, 457, 599-602.	27.8	1,433
135	Oncogenic <i>GNAQ</i> mutations are not correlated with disease-free survival in uveal melanoma. <i>British Journal of Cancer</i> , 2009, 101, 813-815.	6.4	139
136	Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer. <i>Experimental Dermatology</i> , 2009, 18, 548-552.	2.9	4
137	Frequent mutations in the <i>MITF</i> pathway in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 435-444.	3.3	132
138	Genome-wide associations studies for melanoma and nevi. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 527-528.	3.3	25
139	Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1146-1156.	3.7	441
140	Distribution and Significance of Occult Intraepidermal Tumor Cells Surrounding Primary Melanoma. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2024-2030.	0.7	91
141	<i>MC1R</i> Variants Increase Risk of Melanomas Harboring <i>BRAF</i> Mutations. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2485-2490.	0.7	78
142	Absence of <i>PDGFRA</i> Mutations in Primary Melanoma. <i>Journal of Investigative Dermatology</i> , 2008, 128, 488-489.	0.7	16
143	Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E <i>KIT</i> mutation. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 492-493.	3.3	213
144	Expanding the genetic spectrum of pigmentation. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 507-508.	3.3	4

#	ARTICLE	IF	CITATIONS
145	Lack of somatic alterations of <i>MC1R</i> in primary melanoma. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 579-582.	3.3	8
146	Frequent p16-Independent Inactivation of p14ARF in Human Melanoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 784-795.	6.3	94
147	Improving Melanoma Classification by Integrating Genetic and Morphologic Features. <i>PLoS Medicine</i> , 2008, 5, e120.	8.4	322
148	β-Catenin induces immortalization of melanocytes by suppressing <i>p16^{INK4a}</i> expression and cooperates with N-Ras in melanoma development. <i>Genes and Development</i> , 2007, 21, 2923-2935.	5.9	283
149	The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer. <i>Annals of Surgery</i> , 2007, 246, 466-471.	4.2	407
150	Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 37-44.	2.8	89
151	Congenital Melanocytic Nevi Frequently Harbor NRAS Mutations but no BRAF Mutations. <i>Journal of Investigative Dermatology</i> , 2007, 127, 179-182.	0.7	302
152	Constitutive activation of the phosphatidylinositol 3 kinase signalling pathway in acral lentiginous melanoma. <i>British Journal of Dermatology</i> , 2007, 158, 071115063928004-???	1.5	17
153	Establishment of a novel melanoma cell line SMYM-PRGP showing cytogenetic and biological characteristics of the radial growth phase of acral melanomas. <i>Cancer Science</i> , 2007, 98, 958-963.	3.9	13
154	MC1R Germline Variants Confer Risk for BRAF-Mutant Melanoma. <i>Science</i> , 2006, 313, 521-522.	12.6	318
155	Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. <i>Dermatologic Therapy</i> , 2006, 19, 40-49.	1.7	186
156	Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. <i>Nature Cell Biology</i> , 2006, 8, 1053-1063.	10.3	296
157	PI3-Kinase Subunits Are Infrequent Somatic Targets in Melanoma. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1660-1663.	0.7	59
158	In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling. <i>Cancer Research</i> , 2006, 66, 9483-9491.	0.9	271
159	Somatic Activation of KIT in Distinct Subtypes of Melanoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4340-4346.	1.6	1,481
160	Genetic Progression From Melanocyte to Malignant Melanoma. , 2006, , 197-209.		0
161	Genomic Analysis of Blue Nevi and Related Dermal Melanocytic Proliferations. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1214-1220.	3.7	92
162	Distinct Sets of Genetic Alterations in Melanoma. <i>New England Journal of Medicine</i> , 2005, 353, 2135-2147.	27.0	2,501

#	ARTICLE	IF	CITATIONS
163	Genomic Analysis of Melanocytic Neoplasia. <i>Advances in Dermatology</i> , 2005, 21, 81-99.	2.0	12
164	Molecular genetics of melanocytic neoplasia: practical applications for diagnosis. <i>Pathology</i> , 2004, 36, 458-461.	0.6	26
165	Mechanisms of Cell-Cycle Arrest in Spitz Nevi with Constitutive Activation of the MAP-Kinase Pathway. <i>American Journal of Pathology</i> , 2004, 164, 1783-1787.	3.8	99
166	Consumption of the Epidermis. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1621-1625.	3.7	69
167	Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. <i>Oncogene</i> , 2003, 22, 3081-3086.	5.9	123
168	Classifying Melanocytic Tumors Based on DNA Copy Number Changes. <i>American Journal of Pathology</i> , 2003, 163, 1765-1770.	3.8	448
169	Atypical junctional melanocytic proliferations in benign lichenoid keratosis. <i>Human Pathology</i> , 2003, 34, 706-709.	2.0	33
170	Two cases of unusual acral melanocytic tumors: Illustration of molecular cytogenetics as a diagnostic tool. <i>Human Pathology</i> , 2003, 34, 89-92.	2.0	26
171	Determinants of BRAF Mutations in Primary Melanomas. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1878-1890.	6.3	604
172	The Longer Your Telomeres, the Larger Your Nevus?. <i>American Journal of Dermatopathology</i> , 2003, 25, 83-84.	0.6	13
173	Hypothesis: A Role for Telomere Crisis in Spontaneous Regression of Melanoma. <i>Archives of Dermatology</i> , 2003, 139, 667-8.	1.4	30
174	The longer your telomeres, the larger your nevus?. <i>American Journal of Dermatopathology</i> , 2003, 25, 83-4.	0.6	7
175	A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. <i>Human Molecular Genetics</i> , 2002, 11, 3221-3229.	2.9	129
176	Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 1455-1460.	7.1	134
177	Persistent (Recurrent) Spitz Nevi. <i>American Journal of Surgical Pathology</i> , 2002, 26, 654-661.	3.7	117
178	Genetic Changes in Neoplasms Arising in Congenital Melanocytic Nevi. <i>American Journal of Pathology</i> , 2002, 161, 1163-1169.	3.8	228
179	Molecular Cytogenetics as a Diagnostic Tool for Typing Melanocytic Tumors. <i>Recent Results in Cancer Research</i> , 2002, 160, 92-99.	1.8	36
180	Cyclin D1 is a candidate oncogene in cutaneous melanoma. <i>Cancer Research</i> , 2002, 62, 3200-6.	0.9	217

#	ARTICLE	IF	CITATIONS
181	Genomic Approaches to Skin Cancer Diagnosis. Archives of Dermatology, 2001, 137, 1507-11.	1.4	14
182	Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas. Molecular and Cellular Biology, 2001, 21, 2144-2153.	2.3	161
183	Mutations and Copy Number Increase of HRAS in Spitz Nevi with Distinctive Histopathological Features. American Journal of Pathology, 2000, 157, 967-972.	3.8	446
184	Molecular Cytogenetic Analysis of Spitz Nevi Shows Clear Differences to Melanoma. Journal of Investigative Dermatology, 1999, 113, 1065-1069.	0.7	316
185	A lymphohistiocytic variant of anaplastic large cell lymphoma with demonstration of the t(2;5)(p23;q35) chromosome translocation. British Journal of Haematology, 1998, 100, 187-190.	2.5	10
186	Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Journal of Dermatological Science, 1998, 16, S142.	1.9	19
187	<title>Interactive system for registering adjacent tissue sections</title> . , 1998, 3260, 154.		1
188	Primary Cutaneous Natural Killer/ T-Cell Lymphoma. Archives of Dermatology, 1998, 134, 109-111.	1.4	27
189	Adult Rhabdomyoma of the Lip. American Journal of Dermatopathology, 1998, 20, 61-64.	0.6	17
190	Eosinophilic Globules in Spitz Nevi: No Evidence for Apoptosis. American Journal of Dermatopathology, 1998, 20, 551-554.	0.6	25
191	Elevated serum levels of soluble CD30 are associated with atopic dermatitis, but not with respiratory atopic disorders and allergic contact dermatitis. British Journal of Dermatology, 1997, 137, 185-187.	1.5	29
192	Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects. Journal of the American Academy of Dermatology, 1996, 34, 310-312.	1.2	42
193	Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Archives of Dermatological Research, 1996, 288, 353-357.	1.9	85
194	Phospholipase A2 is secreted by murine keratinocytes after stimulation with IL-1 α and TNF- α . Archives of Dermatological Research, 1996, 288, 147-152.	1.9	9
195	Interleukin-10 production in malignant melanoma: Preferential detection of IL-10-secreting tumor cells in metastatic lesions. , 1996, 66, 607-610.		96
196	Melanoma in childhood: An EORTC-MCG multicenter study on the clinico-pathological aspects. , 1996, 68, 317-324.		94
197	Phospholipase A 2 is secreted by murine keratinocytes after stimulation with IL-1 α and TNF- α . Archives of Dermatological Research, 1996, 288, 147-152.	1.9	1
198	Primary Neuroendocrine Carcinoma of the Skin with an Unusual Follicular Lymphocytic Infiltrate of the Dermis. American Journal of Dermatopathology, 1996, 18, 625-628.	0.6	15

#	ARTICLE	IF	CITATIONS
199	Autoantibodies to annexins: a diagnostic marker for cutaneous disorders?. Journal of Dermatological Science, 1994, 8, 194-202.	1.9	17
200	Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients. Cancer, 1993, 72, 741-749.	4.1	99
201	Localization of annexins in normal and diseased human skin. Journal of Dermatological Science, 1993, 6, 225-234.	1.9	25